GLP-1 Oracle
Providers Coverage Costs Reference
Compare providers

51/51 states verified · 25/25 providers audited

GLP-1 receptor agonist

FDA approved

Semaglutide (Ozempic, Wegovy and Rybelsus)

Semaglutide is a licensed GLP-1 receptor agonist. It is sold as Ozempic for type 2 diabetes, Wegovy for chronic weight management and cardiovascular risk reduction, and Rybelsus as an oral tablet for type 2 diabetes.

By John Weeks Updated September 7, 2026

Approved for

  • Type 2 diabetes (Ozempic, Rybelsus)
  • Chronic weight management (Wegovy)
  • Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (Wegovy)

Compounding status

The compounding exception that supplied semaglutide at scale has closed, and the rules differ by country. See the note for this market below.

In United States. The semaglutide shortage was declared resolved in early 2025, ending the 503A compounding exception. On 30 April 2026 the FDA proposed removing semaglutide from the 503B bulks list. Novo Nordisk sells directly through NovoCare, which several telehealth providers have integrated.

Key facts

Approval status
Approved
Direct cash-pay channel
NovoCare

Sources

Every claim above is checked against the primary text, and the date is the day we last opened it.

2 cited records
  1. 1
    NovoCare Pharmacy

    Novo Nordisk Primary text read and checked Checked August 26, 2026

  2. 2
    FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

    U.S. Food and Drug Administration Primary text read and checked Checked August 25, 2026